Seeking Alpha
22 Jun 2026, 20:42 UTC · 21w ago
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
Impact · against what's priced in
Taysha Gene Therapies is providing updated clinical data for TSHA-102, signaling continued progress in its Rett Syndrome program. As a clinical-stage biotech, these updates are critical milestones that drive valuation updates based on drug efficacy and safety profiles.
- TSHA+0.20
No priced-in read yet





